|Description||CPI-203 is a BET bromodomain inhibitor. It inhibits BRD4 in vitro and in cells, and causes G1 cell cycle arrest. It also arrests the growth of T cell acute lymphoblastic leukemia cells in vitro (EC50 = 91.2 nM).|
|B0084-463432||25 mg||$299||In stock|
|B0084-463432||100 mg||$499||In stock|
|B0084-463432||500 mg||$1299||In stock|
|Brife Description||BET Bromodomain inhibitor|
|Storage||Store at -20°C|
|Shelf Life||2 years|
NVS-CECR2-1 is a potent and selective CECR2 (cat eye syndrome chromosome region, candidate 2) inhibitor (IC50 = 47 nM). NVS-CECR2-1 showed no cross reactivity i...
XD 14 is a BET bromodomain inhibitor (Kd = 160, 170, 380, 490, 830 and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2) respectively). XD 14 a...
ARV-771, a pan-BET degrader, is a novel BET-PROTAC with superior in vivo pharmacology that recruits the E3 ligase VHL (Von Hippel-Lindau) to degrade BETPs (Kd= ...
PFI-3, a potent and selective SMARCA2/4 bromodomain inhibitor, is a cell-permeable probe that binds avidly to the structurally-similar SMARCA4 bromodomain (Kd= ...
CPI-203 is a BET bromodomain inhibitor. It inhibits BRD4 in vitro and in cells, and causes G1 cell cycle arrest. It also arrests the growth of T cell acute lymp...
(R)-(-)-JQ1 is the R-isomer and an inactive control of JQ1, a BET bromodomain inhibitor.
TC AC 28
TC AC 28 is a high affinity BET bromodomain ligand (Kd = 40 and 800 nM for Brd2(2) and Brd2(1), respectively) with 20-fold selectively for the second over the f...
PFI-1 is a potent and highly selective protein interaction Inhibitor, which targets BET bromodomain. PFI-1 that efficiently blocks the interaction of BET BRDs...
TPOP146 is a potent and selective CBP/P300 benzoxazepine bromodomain inhibitor with Kd values of 134 nM and 5.02 μM for CBP and BRD4. TPOP146 targets the CBP br...
ISOX INACT is an inactive control probe of the bromodomain of CREB binding protein (CBP) PF-CBP1. It shows negligible activity at CBP and BRD4. It was used to p...
I-BRD9, as a selective cell active chemical probe for BRD9 (pIC50 = 7.3), it exhibits 200-fold selectivity for bromodomain containing protein 9 over the highly ...
TG101209 is a novel and potent JAK2 inhibitor. The induction of cytotoxicity was associated with inhibition of cell cycle progression and induction of apoptosi...
PF-431396 is a dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively).
GSK9311 is a potent and selective inhibitor of the BRPF bromodomain (pIC50= 6.0 and 4.3 for BRPF1 and BRPF2, respectively).
GSK 525768A is a enantiomer analogue of GSK 525762A which is a BET family inhibitor aiming at the bromodomain and has potential effect against cancers and sorts...
TG101348 is a small molecule inhibitor of JAK2 (IC50 = 6 nM) and the related kinases FLT3 (IC50 = 25 nM) and RET (IC50 = 17 nM) with significantly less potent a...
PFI-4 is a potent and selective BRPF1 bromodomain inhibitor with IC50 of 80 nM.
CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor with IC50 of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respect...
Mivebresib is a BET inhibitor with potential antineoplastic activity. It disrupts critical transcription programs that drive prostate cancer growth to induce po...
PF-CBP1, also known as PF-06670910, is a selective CBP/p300 bromodomain inhibitor (IC50 values are 125 and 363 nM, respectively) with >100-fold selectivity for ...